A closer look at these patients revealed that they often had the more indolent ACC-II phenotype, most had <2 prior lines of systemic therapy, few had experienced PD on their immediate prior line of treatment, and somatic alterations in chromatin remodeling genes were common (e.g., BCOR, ARID1A, EP300, and KMT2D). This evidence concerns the gene BCOR and adrenal cortex carcinoma.